Skip to NavigationSkip to content

Boehringer Ingelheim break ground on $217 million Fremont facility

Published on 01/08/17 at 09:51am

Boehringer Ingelheim announced that it had broken ground on its planned $217 million upgrade and expansion of its existing Fermont manufacturing facility. The investment is expected to create a further 300 jobs to the city of Fremont, just south of San Francisco.

The facility produces biologics and biosimilars, with a focus on oncology, rheumatology and immunology. Should the expansion be carried out as planned, the production capability of the plant will be boosted by a third.

The facility currently covers 300,000 square feet and includes development labs, a pilot plant and large-scale bioreactors. The company had acquired the facility from Amgen, back in 2011, as part of a concerted effort to improve its contract biologics production.

“The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California," said Jens Vogel, President and CEO of Boehringer Ingelheim Fremont, Inc. "We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.”

For its part of the commitment, the state provided the company with $25.5 million in two separate tax credits from the state – the largest award given to a pharmaceutical company. The facility is one of a global network of such manufacturing plants, that includes further locations in Germany, Austria and China.

Ben Hargreaves

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches